Provided by Tiger Trade Technology Pte. Ltd.

Anixa Biosciences

3.71
+0.12003.34%
Post-market: 3.64-0.0700-1.89%19:53 EDT
Volume:182.43K
Turnover:673.81K
Market Cap:126.23M
PE:-12.22
High:3.76
Open:3.64
Low:3.60
Close:3.59
52wk High:5.46
52wk Low:2.32
Shares:34.02M
Float Shares:31.87M
Volume Ratio:0.71
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3035
EPS(LYR):-0.3367
ROE:-71.97%
ROA:-41.91%
PB:8.72
PE(LYR):-11.02

Loading ...

Spotlighting Anixa Biosciences And 2 Other Noteworthy Penny Stocks

Simply Wall St.
·
Aug 21

Anixa Biosciences to Present at H.C. Wainwright Global Investment Conference

Reuters
·
Aug 18

Top Executive Makes Bold Move With Fresh Anixa Biosciences Stock Buy

TIPRANKS
·
Aug 04

Anixa Biosciences CEO Amit Kumar Acquires 5,000 Common Shares Valued at $17,350

Reuters
·
Aug 03

Anixa Biosciences CEO Quietly Boosts His Stake With Fresh Insider Buys

TIPRANKS
·
Jul 28

Anixa Biosciences CEO Amit Kumar Acquires 3,000 Common Shares Worth $11,190

Reuters
·
Jul 27

Anixa Biosciences CEO Amit Kumar Acquires 5,000 Common Shares for $17,300

Reuters
·
Jul 21

Insider Move: Anixa Biosciences Director Deepens Stake in the Company

TIPRANKS
·
Jul 21

Anixa Biosciences Director Lewis H. Titterton Jr Acquires 12,000 Common Shares Valued at $41,640

Reuters
·
Jul 21

3 Penny Stocks With Market Caps Over $100M To Consider

Simply Wall St.
·
Jul 20

Anixa Biosciences Director Lewis H. Titterton Jr Acquires $9,172 of Common Shares

Reuters
·
Jul 16

Anixa Biosciences Says Australia Accepts Patent for Breast Cancer Vaccine Technology

Reuters
·
Jul 14

Anixa Biosciences CEO Amit Kumar Buys $15,200 Common Shares

Reuters
·
Jul 13

Anixa Advances Ovarian Cancer CAR-T Trial to Highest Dose Cohort in Phase 1 Study

Reuters
·
Jul 06

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

THOMSON REUTERS
·
Jul 06

Anixa Biosciences - Five Patients Surpass One Year Survival with Durations up to 28 Months

THOMSON REUTERS
·
Jul 06

Anixa Biosciences - no Dose-limiting Toxicities Observed up to Prior Dose Level of 3x10⁶/kg CAR-T Cells

THOMSON REUTERS
·
Jul 06

Anixa Biosciences Coverage Assumed by D. Boral Capital at Buy

Dow Jones
·
Jul 01

Anixa Biosciences assumed with a Buy at D. Boral Capital

TIPRANKS
·
Jun 30

Anixa Biosciences granted first Korean patent for breast cancer vaccine

TIPRANKS
·
Jun 29